See more : Old Market Capital Corporation (OMCC) Income Statement Analysis – Financial Results
Complete financial analysis of SMN Corporation (6185.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SMN Corporation, a leading company in the Internet Content & Information industry within the Communication Services sector.
You may be interested
- Aurora Optoelectronics Co.,Ltd. (600666.SS) Income Statement Analysis – Financial Results
- rakumo Inc. (4060.T) Income Statement Analysis – Financial Results
- BMO ULTRA SHORT TERM US BOND ET (ZUSFF) Income Statement Analysis – Financial Results
- Salt Lake Potash Limited (SO4.L) Income Statement Analysis – Financial Results
- Maslavi Construction Company Ltd (MSLA.TA) Income Statement Analysis – Financial Results
SMN Corporation (6185.T)
Industry: Internet Content & Information
Sector: Communication Services
Website: https://www.so-netmedia.jp
About SMN Corporation
SMN Corporation engages in digital marketing business in Japan and internationally. The company offers VALIS-Engine, an AI engine; Logicad, a demand side platform; and VALIS-Cockpit, a marketing analytics tool. It also provides data collection and analysis, advertising management, and content-based marketing solutions for agencies and advertisers; and creates and distributes ad content for SSPs and media outlets. In addition, the company offers marketing solutions to support advertisation on the web portal of ISP So-Net. The company was incorporated in 2000 and is headquartered in Tokyo, Japan. SMN Corporation is a subsidiary of Sony Network Communications Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.34B | 11.79B | 13.36B | 12.12B | 11.61B | 10.22B | 9.02B | 6.96B | 5.63B | 3.71B |
| Cost of Revenue | 6.74B | 9.18B | 10.23B | 9.30B | 8.77B | 7.93B | 7.07B | 5.56B | 4.49B | 2.89B |
| Gross Profit | 2.60B | 2.61B | 3.13B | 2.82B | 2.84B | 2.28B | 1.95B | 1.40B | 1.14B | 821.24M |
| Gross Profit Ratio | 27.80% | 22.10% | 23.44% | 23.26% | 24.47% | 22.34% | 21.66% | 20.15% | 20.24% | 22.12% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.49B | 2.59B | 3.01B | 2.51B | 2.09B | 1.56B | 1.41B | 1.08B | 844.41M | 0.00 |
| Other Expenses | 0.00 | -23.88M | 70.00K | -4.52M | -787.00K | -1.93M | -1.39M | -527.00K | -1.67M | -1.00M |
| Operating Expenses | 2.49B | 2.59B | 3.01B | 2.51B | 2.09B | 1.56B | 1.41B | 1.08B | 844.41M | 651.01M |
| Cost & Expenses | 9.23B | 11.77B | 13.24B | 11.81B | 10.86B | 9.49B | 8.48B | 6.64B | 5.33B | 3.54B |
| Interest Income | 83.00K | 171.00K | 190.00K | 146.00K | 28.00K | 25.00K | 25.00K | 15.00K | 63.00K | 72.00K |
| Interest Expense | 8.76M | 10.51M | 12.93M | 4.64M | 2.72M | 295.00K | 161.00K | 162.00K | 14.64M | 0.00 |
| Depreciation & Amortization | 835.93M | 819.30M | 881.86M | 630.75M | 521.19M | 381.48M | 273.87M | 189.64M | 110.98M | 47.64M |
| EBITDA | -196.17M | 813.69M | 778.81M | 838.06M | 1.26B | 1.10B | 811.35M | 513.93M | 389.71M | 217.87M |
| EBITDA Ratio | -2.10% | 6.95% | 7.62% | 7.68% | 10.93% | 10.82% | 9.04% | 7.39% | 7.21% | 5.84% |
| Operating Income | 102.21M | 17.26M | 127.28M | 303.88M | 747.88M | 725.62M | 543.02M | 325.00M | 294.97M | 170.23M |
| Operating Income Ratio | 1.09% | 0.15% | 0.95% | 2.51% | 6.44% | 7.10% | 6.02% | 4.67% | 5.24% | 4.58% |
| Total Other Income/Expenses | -1.14B | -33.39M | -243.26M | -101.21M | -12.46M | -8.88M | -5.71M | 131.00K | -16.25M | -66.00K |
| Income Before Tax | -1.04B | -16.13M | -115.98M | 202.67M | 735.41M | 716.74M | 537.31M | 324.13M | 278.73M | 170.16M |
| Income Before Tax Ratio | -11.15% | -0.14% | -0.87% | 1.67% | 6.34% | 7.02% | 5.96% | 4.66% | 4.95% | 4.58% |
| Income Tax Expense | -11.04M | 85.79M | 107.43M | 240.97M | 251.63M | 139.86M | -100.22M | 73.40M | 36.83M | -37.76M |
| Net Income | -1.03B | -117.10M | -228.58M | -38.30M | 483.78M | 576.91M | 637.53M | 250.74M | 241.90M | 207.92M |
| Net Income Ratio | -11.02% | -0.99% | -1.71% | -0.32% | 4.17% | 5.65% | 7.07% | 3.60% | 4.30% | 5.60% |
| EPS | -70.79 | -8.30 | -17.44 | -2.96 | 37.73 | 41.83 | 47.29 | 21.51 | 26.17 | 25.28 |
| EPS Diluted | -70.79 | -8.30 | -17.44 | -2.96 | 35.45 | 41.76 | 47.25 | 19.08 | 20.82 | 25.28 |
| Weighted Avg Shares Out | 14.53M | 14.11M | 13.11M | 12.96M | 12.82M | 13.79M | 13.48M | 11.66M | 9.24M | 8.22M |
| Weighted Avg Shares Out (Dil) | 14.53M | 14.11M | 13.11M | 12.96M | 13.65M | 13.81M | 13.49M | 13.14M | 11.62M | 8.22M |
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2023. “The first quarter was...
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022. “We...
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the third quarter ended September 30, 2022. “This has been an...
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2022. “The first half of...
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2022. “Current events have put...
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company fearlessly leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021....
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the third...
Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the second...
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the first...
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the fourth...
Source: https://incomestatements.info
Category: Stock Reports